Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 399 participants.
Also called NCT05185804
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 399 participants
- Sponsor
- PharmaDiall Ltd.
- Registry
-
NCT05185804
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Russia
- Registry status
- Completed
Technical summary
Registry record NCT05185804. Randomized; no masking; primary purpose treatment. Start 2021-02-08 (actual); primary completion 2021-08-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Trial of Dimolegin (DD217) in Prevention of Thrombotic Complications in Patients With COVID-19
- Condition
- COVID-19
- Condition
- Venous Thromboembolism
- Intervention (Drug)
- Dimolegin
- Intervention (Drug)
- Clexane
- Lead sponsor
- PharmaDiall Ltd.
Record details
- Record id
cardio:ct-nct05185804- Content hash
0c2d259502a8c8661e3a404555482874f1923f447b657600da31a003f3ef35a3